BeyondSpring Pharma, a New York City virtual immuno-oncology cancer company, received China approval to conduct a Phase III trial of its lead drug, plinabulin. The China arm will be part of a global trial that expects enroll 550 subjects in the US, China, Australia and New Zealand. Plinabulin, which has an anti-angiogenesis mechanism, will be administered in combination with docetaxel in patients who have non-small cell lung cancer (NSCLC). Approval for the US arm of the trial was granted in July 2015.
